Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Participants

Part of paid clinical trials in Salt Lake City, Utah.

Sponsor
Vertex Pharmaceuticals Incorporated
Study ID
NCT07570069
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Pain

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • Suzetrigine — DRUG
    Tablet for oral administration.
  • Efavirenz — DRUG
    Tablet for oral administration.

Study Details

The purpose of the study is to evaluate the pharmacokinetics (PK) of Suzetrigine (SUZ) and its metabolite in the absence and presence of efavirenz, a moderate CYP3A inducer. In addition, the purpose is to evaluate the safety and tolerability of SUZ when administered in the absence and presence of efavirenz.

Key Dates

Start date
May 7, 2026
Status verified
Apr 2026
Primary completion
Jul 11, 2026
Completion
Jul 11, 2026

Study Design

Enrollment
18 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: SUZ and Efavirenz
    Participants will receive a single dose of SUZ on Days 1 through 15. Participants will also receive a single dose of SUZ in the morning followed by a single dose of efavirenz in the evening on Days 16 through 30.

Primary Outcome Measure

Maximum Observed Plasma Concentration (Cmax) of SUZ and its Metabolite in the Absence and Presence of Efavirenz [ Time Frame: Day 15 and Day 30 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
ICON - Utah - Salt Lake City OfficeSalt Lake CityUtah84124-

Find similar trials in Salt Lake City, UT

By research site
ICON - Utah - Salt Lake City Office· Salt Lake City, UT

Related Studies